莫西沙星对老年肾功能不全社区获得性肺炎的治疗效果及安全性评价  

Efficiency and safety of moxifloxacin in treatment of elderly community acquired pneumonia with renal dysfunction

作　　者：杭晨晨[1] 王烁[1] 

机构地区：[1]首都医科大学附属北京朝阳医院急诊科,北京100020

出　　处：《中国急救医学》2014年第8期685-688,共4页Chinese Journal of Critical Care Medicine

摘　　要：目的：评估莫西沙星在老年肾功能不全社区获得性肺炎（ community acquired pneumonia， CAP）中的治疗效果及安全性，为临床治疗老年肾功能不全CAP选择安全、高效的抗菌药物。方法选取2011-01～2013-12在急诊科住院的128例老年CAP患者，根据肾功能状况分为肾功能正常组（n＝63）和肾功能不全但未透析组（n＝65），均给予莫西沙星治疗，观察临床疗效及不良反应。结果肾功能正常组与肾功能不全组比较，治疗有效率（81．0％vs．87．7％，P＝0．294），细菌清除率（80．56％vs．88．37％，P＝0．335），不良反应发生率（7．93％vs．9.23％，P＝0.794）均差异无统计学意义。无论是肾功能正常组，还是肾功能异常组，在整个治疗期间莫西沙星血药浓度保持平稳，两组之间差异无统计学意义（P＞0．05）。结论莫西沙星治疗老年肾功能不全相关肺炎临床效果明显，不良反应少，安全可靠。Objective To evaluate the effectiveness and safety of moxifloxacinin treatment of community acquired pneumonia in elderly patients with renal dysfunction , so as to provide safe and effective antibiotics for the treatment of community acquired pneumonia for patients . elderly renal dysfunction .Methods A total of 128 elderly patients with community acquired pneumonia , who enrolled the emergency department of the hospital from Jan 2011 to Dec 2013 , were divided into two groups according to the renal function .The normal group （ n =63 ） and the renal dysfunction group without hemodialysis （ n =65 ） were both treated with moxifloxacin .The clinical efficacies and the adverse reactions were observed .Results There was no statistically difference in the clinical effective rates （81.0% vs.87.7%, P=0.294）, the pathogensclearance rate （80.56% vs.88.37%, P=0.335） and the incidence of the adverse reactions （7.93% vs.9.23%, P=0.794） between the two groups.There was no significant difference of moxifloxacin plasma concentration between the two groups at each time point.The plasma concentration was stable in the whole protocol .Conclusion Moxifloxacincan achieve good clinic effect in the treatment of community acquired pneumonia with renal dysfunction in elderly patients with less adverse reaction .

关 键 词：莫西沙星 社区获得性肺炎(CAP) 老年人 肾功能不全 

分 类 号：R563.1[医药卫生—呼吸系统]